Copyright
©The Author(s) 2019.
World J Hepatol. Jan 27, 2019; 11(1): 50-64
Published online Jan 27, 2019. doi: 10.4254/wjh.v11.i1.50
Published online Jan 27, 2019. doi: 10.4254/wjh.v11.i1.50
Reference | Country | LT type | n | Biomarkers | Time of biomarker test | Risk factors by multivariate analysis | Risk score |
Yoshizumi et al[95], 2013 | Japan | LDLT | 104 | AFP > 400, DCP > 300, NLR ≥ 4 | Not specified | NLR, tumor size + number ≥ 8 | No |
Na et al[96], 2014 | Korea | LDLT | 224 | AFP ≥ 100, NLR ≥ 6, CRP ≥ 1, | Day of LT | NLR ≥ 6 and AFP ≥ 100 | Prognostic factor score: NLR ≥ 6 and CRP ≥ 1 (one point each) |
Shindoh et al[80], 2014 | Japan | LDLT | 124 | AFP, DCP, NLR | Day before LT, maximum and mean values within 90 d before LT | Tumor ≥ 5, MVI, mean NLR and maximum AFP and DCP before LT | Tokyo criteria, AFP > 250 and DCP > 450 (one point each) |
Lai et al[78], 2014 | Belgium | DDLT | 146 | AFP > 200, NLR > 5.4, PLR > 150 | At inclusion on the waiting list, at LT, | AFP, NLR and PLR in univariate analysis | No |
Parisi et al[79], 2014 | UK | DDLT | 150 | NLR ≥ 5, PLR ≥ 150, IBI score | Day of LT | Absence of neoadjuvant therapy, beyond Milan criteria on explant | No |
Harimoto et al[99], 2016 | Japan | LDLT | 190 | DCP ≥ 300, NLR ≥ 2.66, PLR ≥ 70.4, CRP ≥ 0.27 | Not specified | NLR, DCP, and tumor number ≥ 5 | No |
Wang et al[97], 2016 | China | DDLT/LDLT | 248 | NLR continuous, AFP > 400 | Within 1 wk before LT | NLR , AFP > 400, age, tumor number and size | Model TFS: 1.094 × tumor number (≤ 3, 0 points; > 3 (1 point) + 0.094 × maximum tumor diameter + 0.754 × AFP (≤ 400, 0 points; > 400, 1 point) + 0.085 × NLR -0.024 × age |
Halazun et al[98], 2017 | United States | DDLT/LDLT | 339 | NLR ≥ 5, AFP | NLR at day of LT; serial AFP at HCC diagnosis, before pre-LT treatment and at LT. | Tumor size and number, NLR ≥ 5, maximum pre-LT AFP, vascular invasion and poor differentiated tumors | MoRAL score: (1) pre-MoRAL: NLR ≥ 5 (6 points) + AFP > 200 (4 points) + largest tumor size > 3 cm by imaging (3 points); (2) post-MoRAL: grade IV tumors (6 points) + vascular invasion (2 points) + tumor size > 3 on pathology (3 points) + tumor number > 3 on pathology (2 points); and (3) combined score. |
Fu et al[100], 2018 | China | LDLT | 150 | NLR, PLR, MLR, SII | Within 1 wk before LT | No association | No |
- Citation: Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019; 11(1): 50-64
- URL: https://www.wjgnet.com/1948-5182/full/v11/i1/50.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i1.50